about
Growth factors for treating diabetic foot ulcersARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro.Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia.Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle.
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Actovegin®: a biological drug for more than 5 decades.
@ast
Actovegin®: a biological drug for more than 5 decades.
@en
Actovegin®: a biological drug for more than 5 decades.
@nl
type
label
Actovegin®: a biological drug for more than 5 decades.
@ast
Actovegin®: a biological drug for more than 5 decades.
@en
Actovegin®: a biological drug for more than 5 decades.
@nl
prefLabel
Actovegin®: a biological drug for more than 5 decades.
@ast
Actovegin®: a biological drug for more than 5 decades.
@en
Actovegin®: a biological drug for more than 5 decades.
@nl
P2093
P2860
P1476
Actovegin®: a biological drug for more than 5 decades.
@en
P2093
Florian Buchmayer
Gereon Lauer
Gerfried Nell
Harald H Sitte
Johannes Pleiner
Martin W Elmlinger
P2860
P2888
P356
10.1007/S10354-011-0865-Y
P577
2011-02-01T00:00:00Z
P6179
1001648182